Barely Significant
← all excerpts

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.

Cancer Chemother Pharmacol · 2020 · PMC7188706 · PMID 32274565

Europe PMCDOI
2
hedged sentences
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

borderline significantP = 0.06so close (0.05 < p ≤ 0.1)
Although this was only borderline significant ( P = 0.06) in this small patient group, the feasibility of sorafenib drug monitoring to achieve a target exposure supports this strategy to improve controlled drug exposure.

also in 11,409 other papers

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)
The difference between week 1 and week 3 showed a trend towards an improved prediction of exposure ( P = 0.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.